Epstein-Barr virus and lymphomas

Cancer Surveys

Volumn 33, Issue , 1998, Pages 99-123

  Brooks, L A ^a   Crook, T ^b   Crawford, D H ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; GLOBOTRIAOSYLCERAMIDE; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TUMOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BURKITT LYMPHOMA; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA TUMOR VIRUS; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; NASOPHARYNX CANCER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECIPIENT; REVIEW; T CELL LYMPHOMA; VIRUS EXPRESSION;

EID: 0032419718     PISSN: 02612429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (181)

1. Allday MJ, Sinclair A, Parker G, Crawford DH and Farrell PJ (1995) Epstein-Barr virus efficiently immortalises human B cells without neutralising the function of p53. EMBO Journal 14 1382-1391
2. Altiok E, Minarovits J, Hu LF, Contreras-Brodin B, Klein G and Ernberg I (1992) Host-cell-phenotype-dependent control of BCR2/BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proceedings of the National Academy of Sciences of the USA 89 905-909
3. Anagnostopoulos I, Herbst H, Niedobitek G and Stein H (1989) Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 74 810-816
4. Anagnostopoulos I, Hummel M, Finn T et al (1992) Heterogeneous Epstein-Barr virus infection patterns in peripheral T cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80 1804-1812
5. Anagnostopoulos I, Hummel M, Kreschel C and Stein H (1995) Morphology, immunophenotype and distribution of latently and/or productively Epstein-Barr virus infected cells in acute infectious mononucleosis; implications for the individual infection route of Epstein-Barr virus. Blood 85 744-750
6. Azim T and Crawford DH (1988) Lymphocytes activated by the Epstein-Barr virus to produce immunoglobulin do not express CD23 or become immortalized. International Journal of Cancer 42 23-28
7. Baer R, Bankier AT, Biggin MD et al (1984) DNA sequence and expression of the B95.8 Epstein-Barr virus genome. Nature 310 207-211
8. Baichwal VR and Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2 461-467
9. Beral V, Peterman T, Berkelman R and Jaffe H (1991) Aids-associated non-Hodgkin lymphoma. Lancet 337 805-809
10. Bernard SM, Cartwright RA, Darwin CM et al (1987) Hodgkin's disease: case control epidemiological study in Yorkshire. British Journal of Cancer 55 85-90
11. Bhatia K, Raj A, Gutierrez MI et al (1996) Variation in the sequence of Epstein-Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Oncogene 13 177-181
12. Billaud M, Rousset F, Calender A et al (1990) Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus. Blood 75 1827-1833
13. Bogedain C, Wolf H, Modrow S, Stuller G and Jilg W (1995) Specific cytotoxic T lymphocytes recognise the immediate early transactivator Zta of Epstein-Barr virus. Journal of Virology 69 4872-4879
14. Bornkamm GW, Stein H, Lennert K, Ruggeberg F, Bartels H and zur Hausen H (1976) Attempts to demonstrate virus-specific sequences in human tumors. EB virus DNA in European Burkitt lymphoma and immunoblastic lymphadenopathy with excessive plasmacytosis. International Journal of Cancer 17 177-181
15. Brooks L and Thomas JA (1995) The significance of Epstein-Barr virus in the pathogenesis of lymphoid and epithelial neoplasia. Current Diagnostic Pathology 2 163-174
16. Brooks L, Yao Q-Y, Rickinson AB and Young LS (1992) Epstein-Barr virus (EBV) latent gene transcription in nasopharyngeal carcinoma biopsies: co-expression of EBNA 1, LMP 1 and LMP 2 transcripts. Journal of Virology 66 2689-2697
17. Brooks LA, Lear AL, Young LS and Rickinson AB (1993) Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. Journal of Virology 67 3182-3190
18. Burkitt DP (1962) Determining the climatic limitations of a childrens cancer common in Africa. British Medical Journal ii 1019-1023
19. Cannell EJ, Farrell PJ and Sinclair AJ (1996) Epstein-Barr virus exploits the normal cell pathway to regulate RB activity during immortalisation of primary B cells. Oncogene 13 1413-1421
20. Chadburn A, Cesarman E and Knowles DM (1997) Molecular pathology of post-transplantation lymphoproliferative disorders. Seminars in Diagnostic Pathology 14 15-26
21. Chen HL, Lung MM, Sham JS, Choy DT, Griffin BE and Ng MH (1992) Transcription of the BamHIA region of the EBV genome in NPC tissues and B cells. Virology 191 193-201
22. Chen ML, Tsai CN, Liang CL et al (1992) Cloning and characterisation of the latent membrane protein (LMP1) of a specific Epstein-Barr virus variant derived from nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7 2131-2140
23. Cheung ANY, Khoo US, Kwong KY, Srivastava G and Collins RJ (1993) Epstein-Barr virus in carcinoma of the vulva. Journal of Clinical Pathology 46 849-851
24. Cohen JI and Kieff E (1991) An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. Journal of Virology 65 5880-5885
25. Cohen JI, Wang F, Mannick J and Kieff E (1989) Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proceedings of the National Academy of Sciences of the USA 86 9558-9562
26. Cohen JI, Wang F and Kieff E (1991) Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. Journal of Virology 65 2545-2554
27. Cordier M, Calender A, Billaud M et al (1990) Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. Journal of Virology 64 1002-1013
28. Crook T and Vousden KH (1994) Interaction of HPV E6 with p53 and associated proteins. Biochemical Society Transactions 22 52-55
29. Deacon EM, Pallesen G, Niedobitek G et al (1993) Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. Journal of Experimental Medicine 177 339-349
30. Delecluse HJ, Rouault JP, Jeammot B, Kremmer E, Bastard C and Berger F (1995) Bcl6/Laz3 rearrangements in post-transplant lymphoproliferative disorders. British Journal of Haematology 91 101-103
31. Dimery IW, Lee JS, Blick M, Pearson G, Spitzer G and Hong WK (1988) Association of the Epstein-Barr virus with lymphoepithelioma of the thymus. Cancer 61 2475-2480
32. Edwards RH and Raab-Traub N (1994) Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. Journal of Virology 68 1309-1315
33. Effert P, Mcloy R, Abdel-Hamid M et al (1992) Alterations of the p53 gene in nasopharyngeal carcinoma. Journal of Virology 66 3768-3775
34. Enblad G, Sandvej K, Lennette E et al (1997) Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. International Journal of Cancer 72 394-397
35. Epstein MA, Achong BG and Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet ii 702-703
36. Fahraeus R, Li-Fu H, Ernberg I et al (1988) Expression of Epstein-Barr virus genome in nasopharyngeal carcinoma. International Journal of Cancer 42 329-338
37. Farrell PJ, Allen GJ, Shanahan F, Vousden KH and Crook T (1991) p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO Journal 10 2879-2887
38. Fingeroth JD, Weiss JJ, Tedder TF, Strominger JL, Biro PA and Fearon DT (1984) Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of Sciences of the USA 81 4510-4514
39. Fischer E, Delibrias C and Kazatchkine MD (1991) Expression of CR2(the C3d/EBV receptor, CD21) on normal human peripheral blood lymphocytes. Journal of Immunology 146 865-869
40. Fries, KL, Miller WE and Raab-Traub N (1996) Epstein-Barr virus latent membrane protein blocks p53-mediated apoptosis through the induction of the A20 gene. Journal of Virology 70 8653-8659
41. Fries KL, Sculley TB, Webster-Cyriaque J, Rajadurai P, Sadler RH and Raab-Traub N (1997) Identification of a novel protein encoded by the BamHIA region of the Epstein-Barr virus. Journal of Virology 71 2765-2771
42. Gaidano G, Ballerini P, Gong JZ et al (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the USA 88 5413-5417
43. Gaidano G, Pastore C, Gloghini A, Volpe G, Ghia P and Carbone A (1996) AIDS-related non-Hodgkin's lymphomas: molecular genetics, viral infection and cytokine deregulation. Acta Haematologica 95 193-198
44. Gilligan K, Rajadurai P, Lin J et al (1991) Expression of the Epstein-Barr virus BamHIA fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. Journal of Virology 65 6252-6259
45. Gordon J (1989) Relationship between Epstein-Barr virus and the B lymphocyte. Advances in Viral Oncology 8 173-186
46. Grasser FA, Murray PG, Kremmer E et al (1994) Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA-1): immunohistological detection of EBNA-1 in the malignant cells of Hodgkin's disease. Blood 84 3792
47. Gregory CD, Edwards CF, Milner A et al (1988a) Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. International Journal of Cancer 42 213-220
48. Gregory CD, Murray RJ, Edwards CF and Rickinson AB (1988b) Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumour cell escape from virus-specific T cell surveillance. Journal of Experimental Medicine 167 1811-1824
49. Gregory CD, Rowe M and Rickinson AB (1990) Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. Journal of General Virology 71 1481-1495
50. Grossman SR, Johanssen E, Tong X, Yalamanchili R and Kieff E (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proceedings of the National Academy of Sciences of the USA 91 7568-7572
51. Gulley ML, Eagan PA, Quintanilla-Martinez L et al (1994) Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease-association with mixed cellularity subtype and Hispanic American ethnicity. Blood 83 1595-1602
52. Gupta RK, Patel K, Bodmer WF and Bodmer JG (1993) Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. Proceedings of the National Academy of Sciences of the USA 90 2817-2821
53. Hamilton-Dutoit SJ and Pallesen G (1992) A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. American Journal of Pathology 140 1315
54. Hamilton-Dutoit SJ, Rea D, Raphael M et al (1993) Epstein-Barr virus latent gene expression and tumour cell phenotype in aquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. American Journal of Pathology 143 1072-1085
55. Hammarskjold ML and Simurda MC (1992) Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-KB activity. Journal of Virology 66 6496-6501
56. Hammerschmidt W and Sugden B (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340 393-397
57. Hanto DW, Frizzera G, Gajl-Peczalska KJ and Simmons RL (1985) Epstein-Barr virus, immunodeficiency and B cell lymphoproliferation. Transplantation 39 461-472
58. Haque T, Thomas JA, Falk KI et al (1996) Transmission of donor Epstein-Barr virus in transplanted organ causes lymphoproliferative disease in EBV seronegative recipients. Journal of General Virology 77 1169-1172
59. Haque T, Amlot P, Helling N et al (1998) Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. Journal of Immunology 160 6204-6209
60. Harabuchi Y, Yamanaka N, Kataura A et al (1990) Epstein-Barr virus in nasal T cell lymphomas in patients with lethal midline granuloma. Lancet ii 128-130
61. Harada S and Kieff E (1997) Epstein-Barr virus nuclear protein LP stimulates EBNA2 acidic domain-mediated transcriptional activation. Journal of Virology 71 6611-6618
62. Henderson S, Rowe M, Gregory C et al (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein-1 protects infected B cells from programmed cell death. Cell 65 1107-1115
63. Henkel T, Ling PD, Hayward SD and Peterson MG (1994) Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal binding protein J. Science 265 92-95
64. Herbst H, Dallenbach F, Hummel M et al (1991) Epstein-Barr virus latent membrane protein expressed in Hodgkin's and Reed Sternberg cells. Proceedings of the National Academy of Sciences of the USA 88 4766-4770
65. Hitt MM, Allday MJ, Hara T et al (1989) EBV gene expression in an NPC-related tumour. EMBO Journal 8 2639-2651
66. Hu LF, Zabarovsky ER, Chen F et al (1991) Isolation and sequencing of the EBV BNLF1 gene (LMP-1) from a Chinese nasopharynx carcinoma. Journal of Virology 72 2399-2409
67. Hu LF, Chen F, Zheng X et al (1993) Clonability and tumorigenicity of human epithelial cells expressing the EBV-encoded membrane protein LMP1. Oncogene 8 1575-1583
68. Huen DS, Henderson SA, Croom-Carter D and Rowe M (1995) The Epstein-Barr virus latent membrane protein 1 (LMP-1) mediates activation of NF-KB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10 549-560
69. Imai S, Koizumi S, Sugiura M et al (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proceedings of the National Academy of Sciences of the USA 91 9131-9135
70. Inman GJ and Farrell PJ (1995) Epstein-Barr virus EBNA-LP and transcription regulation properties of pRb, p107, and p53 in transfection assays. Journal of General Virology 76 2141-2149
71. Jarrett RF, Gallagher A, Jones DB et al (1991) Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. Journal of Clinical Pathology 44 844-848
72. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E and Grossman SR (1995) Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by JK and PU.1. Journal of Virology 69 253-262
73. Johansson B, Klein G, Henle W and Henle G (1970) Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukaemia. I Hodgkin's disease. International Journal of Cancer 6 450-462
74. Johnson RJ, Stack M, Hazlewood SA et al (1998) The 30-base-pair deletion in Chinese varieants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. Journal of Virology 72 4038-4048
75. Kahn G, Gupta RK, Coates PJ and Slavin G (1993) Epstein-Barr virus infection and bcl-2 protooncogene expression. Separate events in the pathogenesis of Hodgkin's disease? American Journal of Pathology 143 1270-1274
76. Karran L, Gao Y, Smith PR and Griffin BE (1992) Expression of a family of complementary transcripts in Epstein-Barr virus-infected cells. Proceedings of the National Academy of Sciences of the USA 89 8058-8062
77. Kaye KM, Izumi KM and Kieff E (1993) Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the USA 90 9150-9154
78. 1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO Journal 14 88-96
79. Kerr B, Lear AL, Rowe M et al (1992) Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187 189-204
80. Khanim F, Yao Q-Y, Niedobitek G, Sihota S, Rickinson AB and Young LS (1996) Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographical locations. Blood 88 3491-3501
81. Kieff E (1995) Epstein-Barr virus: increasing evidence of a link to carcinoma. New England Journal of Medicine 333 724-726
82. Klein G (1979) Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proceedings of the National Academy of Sciences of the USA 76 2442-2446
83. Klein G and Klein E (1985) Myc/Ig juxtaposition by chromosomal translocations: some new insights, puzzles and paradoxes. Immunology Today 6 208-215
84. Knecht H, Bachmann E, Brousset P et al (1993) Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82 2937-2942
85. Knecht H, Bachmann E, Brousset P et al (1995) Mutational hotspots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10 523-528
86. Knutson JC (1990) The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. Journal of Virology 64 2530-2536
87. Korbjuhn P, Anagnostopoulos I, Hummel M et al (1993) Frequent latent Epstein-Barr virus infection of neoplastic T cells and bystander B cells in human immunodeficiency virus-negative peripheral pleomorphic T cell lymphomas. Blood 82 217-223
88. Laherty CD, Hu HM, Opipari AW, Wang F and Dixit VM (1992) The Epstein-Barr virus LMP-1 gene product induces A20 zinc finger protein expression by activating nuclear factor KB. Journal of Biological Chemistry 267 24157-24160
89. Lanier A, Clift SR, Bornkamm G, Henle W, Goepfort H and Raab-Traub N (1991) Epstein-Barr virus and malignant lymphoepithelial lesions of the salivary gland. Arctic Medical Research 50 55-61
90. Laux G, Economou A and Farrell PJ (1989) The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. Journal of General Virology 70 3079-3084
91. Leder P, Battey J, Lenoir G et al (1983) Translocations among antibody genes in human cancer. Science 222 765-771
92. Lenoir GM and Bornkamm GW (1987) Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. Advances in Viral Oncology 7 173-206
93. Leoncini L, Vindigni C, Megha T et al (1993) Epstein-Barr virus and gastric cancer: data and unanswered questions. International Journal of Cancer 53 898-901
94. Levitskaya J, Coram M, Levitsky V et al (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature 375 685-688
95. Li S-N, Chang Y-S and Liu S-T (1996) Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12 2129-2135
96. MacMahon EME, Glass G, Hayward SD et al (1991) Epstein-Barr virus in AIDS related primary central nervous system lymphoma. Lancet 338 969-973
97. Magrath I (1990) The pathogenesis of Burkitt's lymphoma. Advances in Cancer Research 55 133-269
98. Mannick JB, Cohen J, Birkenbach M, Marchini A and Kieff E (1991) The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. Journal of Virology 65 6826-6837
99. Martin JM, Veis D, Korsmeyer SJ and Sugden B (1993) Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of Bcl-2. Journal of Virology 676 5269-5278
100. Miller CL, Lee JH, Kieff E and Longnecker R (1994) An integral membrane protein (LMP-2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proceedings of the National Academy of Sciences of the USA 91 772-776
101. Miller CL, Burkhardt AL, Lee JH et al (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein tyrosine kinases. Immunity 2 155-166
102. Minarovits J, Hu LF, Marcsek Z, Minarovits-Kormuta S, Klein G and Ernberg I (1991) Host cell phenotype dependent methylation patterns of Epstein-Barr virus DNA. Journal of General Virology 72 1591-1599
103. Minarovits J, Hu LF, Imai S et al (1994) Clonality expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. Journal of General Virology 75 77-84
104. Miyashita E, Yang B, Lam KMC, Crawford DH and Thorley-Lawson DA (1995) A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80 593-601
105. Morente MM, Piris MA, Abraira VA et al (1997) Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus latent membrane protein 1 expression. Blood 90 2429-2436
106. Mosialos G, Birkenbach M, Yalamanchili R, van Arsdale T, Ware C and Kieff E (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80 389-399
107. Mueller N, Evans A, Harris NL et al (1989) Hodgkin's disease and Epstein-Barr virus. Altered anti-body pattern before diagnosis. New England Journal of Medicine 320 689-695
108. Munoz N, Davison RJL, Witthoff B, Ericsson JE and De Thé G (1978) Infectious mononucleosis and Hodgkin's disease International Journal of Cancer 22 10
109. Murray RJ, Kurilla MG, Brooks JM et al (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implication for the immune control of EBV-positive malignancies. Journal of Experimental Medicine 176 157-168
110. Neri A, Barrigo F, Inghirami G et al (1991) Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 77 1092-1095
111. Nevins JR and Vogt PK (1996) Cell transformation by viruses, In: Fields BN, Knipe DM and Howley PM (eds). Fields Virology, pp 301-343, Lippincott-Raven, Philadelphia, Pennsylvania
112. Niedobitek G, Herbst H, Young LS et al (1992) Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood 79 2520-2526
113. Niedobitek G, Rowlands DC, Young LS et al (1993) Overexpression of p53 in Hodgkin's disease: lack of correlation with Epstein-Barr virus infection. Journal of Pathology 169 207
114. Niedobitek G, Kremmer E, Herbst L et al (1997) Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane 2A in Hodgkin's disease and infectious mononucleosis. Blood 90 1664-1672
115. Nilsson K and Klein G (1982) Phenotypic and cytogenetical characteristics of human B-lymphoid lines and their relevance for the etiology of Burkitt's lymphoma. Advances in Cancer Research 37 319-380
116. Nitsche F, Bell A and Rickinson AB (1997) Epstein-Barr virus leader protein enhances EBNA 2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain. Journal of Virology 71 6619-6628
117. Nonkwelo C, Ruf IK and Sample J (1997) Interferon independent and induced regulation of Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma. Journal of Virology 71 6887-6897
118. Ott G, Ott M, Feller AC, Seidl and Muller-Hermelink HK (1992) Prevalence of Epstein-Barr virus DNA in different T cell lymphoma entities in a European population. International Journal of Cancer 51 562-567
119. Pallesen G, Hamilton-Dutoit SJ, Rowe M and Young LS (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337 320-322
120. Pallesen G, Hamilton-Dutoit SJ and Zhou XG (1994) The association of Epstein-Barr virus (EBV) with T-cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Advances in Cancer Research 62 179-239
121. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ and Allday MJ (1996) Epstein-Barr virus nuclear antigen EBNA3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13 2541-2549
122. Penn I (1991) The changing pattern of posttransplant malignancies. Transplant Proceedings 23 1101-1103
123. Perera SM, Johannessen I, Thomas JA, Brooks LA, N'Jie Jobe J and Crawford DH (1996) Growth of Epstein-Barr virus-associated B-Lymphoproliferative disease tissue in a severe combined immunodeficient mouse. Blood 88 1123-1125
124. Perera SM, Thomas JA, Burke M and Crawford DH (1998) Analysis of the T cell microenvironment in Epstein-Barr virus related post-transplantation B lymphoproliferative disease. Journal of Pathology 184 177-181
125. Polack A, Hortnagel K, Pajic A et al (1996) c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proceedings of the National Academy of Sciences of the USA 93 10411-10416
126. Pope JH, Horne MK and Scott W (1968) Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. International Journal of Cancer 3 857-866
127. Raab-Traub N and Flynn K (1986) The structure of the termini of the Epstein-Barr virus as a marker of clonal proliferation. Cell 47 883-889
128. Rickinson AB and Gregory CD (1988) Burkitt's lymphoma. Transactions of the Royal Society of Tropical Medicine and Hygiene 82 657-659
129. Rickinson AB and Kieff E (1996) Epstein-Barr virus. In: Fields BN, Knipe DM and Howley PM (eds). Fields Virology, pp 2397-2446. Lippincott-Raven, Philadelphia, Pennsylvania
130. Robertson ES, Tomkinson B and Kieff E (1994) An Epstein-Barr virus with a 58-kilobase pair deletion that includes BARF0 transforms B lymphocytes in vitro. Journal of Virology 68 1449-1458
131. Robertson KD and Ambinder RF (1997) Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. Journal of Virology 71 6445-6454
132. Robertson KD, Manns A, Swinnen LJ, Zong C, Gulley ML and Ambinder RF (1996) CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 88 3129-3136
133. Rooney CM, Gregory CD, Rowe M et al (1986) Endemic Burkitt's lymphoma: phenotypic analysis of tumour biopsy cells and of derived cell lines. Journal of the National Cancer Institute 77 681-687
134. Rooney CM, Smith CA, Ng CYC et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein Barr virus related lymphoproliferation. Lancet 345 9-12
135. Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ and Rickinson AB (1986) Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO Journal 5 2599-2607
136. Rowe M, Rooney CM, Rickinson AB et al (1985) Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. International Journal of Cancer 35 435-441
137. Rowe M, Rowe DT, Gregory CD et al (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO Journal 6 2743-2751
138. Rowe M, Young LS, Crocker J, Stokes H, Henderson S and Rickinson AB (1991) Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. Journal of Experimental Medicine 173 147-158
139. Rowe M, Lear A, Croom-Carter D, Davies AH and Rickinson AB (1992) Three pathways of Epstein-Barr virus gene activation from EBNA-1-positive latency in B lymphocytes. Journal of Virology 66 122-131
140. Rowe M, Peng-Pilon M, Huen DS et al (1994) Upregulation of Bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell specific response that is delayed relative to NF-KB and to induction of cell surface markers. Journal of Virology 68 5602-5612
141. Rowe M, Khanna R, Jacob CA et al (1995) Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein 1: coordinate upregulation of peptide transporters and HLA class I antigen expression. European Journal of Immunology 25 1374-1384
142. Sample J, Liebowitz D and Kieff E (1989) Two related Epstein-Barr virus membrane proteins are encoded by separate genes. Journal of Virology 63 933-937
143. Sample J, Henson EB and Sample C (1992) The Epstein-Barr virus nuclear protein 1 promoter active in type 1 latency is autoregulated. Journal of Virology 66 4654-4661
144. Schaefer BC, Strominger JL and Speck SH (1995) Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proceedings of the National Academy of Sciences of the USA 92 10565-10569
145. Schaefer BC, Paulson E, Strominger JL and Speck SH (1997) Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency. Molecular and Cellular Biology 17 873-886
146. Scheinfeld AG, Nador RG, Cesarman E, Chadburn A and Knowles DM (1997) Epstein-Barr virus latent membrane protein 1 deletion in post-transplantation lymphoproliferative disorders. American Journal of Pathology 151 805-812
147. Shaw S, Ginther-Luce GE, Quinones R, Gress RE, Springer TA and Sanders ME (1986) Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 323 262-264
148. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO Journal 13 3321-3328
149. Sjoblom A, Jansson A, Yang W, Lain S, Nilsson T and Rymo L (1995) PU-box binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. Journal of General Virology 76 2679-2692
150. Smith PR, Gao Y, Karran L, Jones MD, Snudden D and Griffin BE (1993) Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus associated tumors. Journal of Virology 67 3217-3225
151. Speck SH and Strominger JL (1989) Transcription of Epstein-Barr virus in latently infected growth-transformed lymphocytes. Advances in Viral Oncology 8 133-150
152. Srinivas SK and Sixbey JW (1995) Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. Journal of Virology 69 8155-8158
153. Starzl TE, Porter KA, Iwatsuki S et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet i 583-587
154. Su IJ, Hsieh HC, Lin KH et al (1990) Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood 77 799-808
155. Sun Y, Hegamyer G, Cheng Y-J and Chen I-H (1992) An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the USA 89 6516-6520
156. Sung NS, Wilson J and Pagano JS (1993) Characterization of cis-acting elements of the BamHIF promoter of EBV, In: Tursz T, Pagano JS, Ablashi DV, de The G, Lenoir G and Pearson GR (eds). The Epstein-Barr Virus and Associated Diseases, pp 239-242, INSERM/John Libbey Eurotext Ltd, London
157. Sung NS, Wilson J, Davenport N, Sista D and Pagano JS (1994) Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor. Molecular and Cellular Biology 14 7144-7152
158. Szekely L, Selivanova G, Magnussen K, Klein G and Wilman K (1993) EBNA-5 an Epstein-Barr virus encoded nuclear antigen binds to the retinoblastoma and p53 proteins. Proceedings of the National Academy of Sciences of the USA 90 5455-5459
159. Tao Q, Robertson KD, Manns A, Hildesheim A and Ambinder RF (1998) The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated and methylation sensitive. Journal of Virology 72 7075-7083
160. Thomas JA and Crawford DH (1993) Biology of lymphoproliferative diseases in transplant patients, In: Rose M and Yacoub M (eds). Immunology of Heart and Lung Transplantation, pp 243-260, Edward Arnold, London
161. Thomas JA, Hotchin NA, Allday MJ et al (1990) Immunohistology of Epstein-Barr virus-associated antigens in B-cell disorders from immunocompromised individuals. Transplantation 49 944-953
162. Thomas JA, Cotter F, Hanby AM et al (1993) Epstein-Barr virus related oral T-cell lymphoma associated with human immunodeficiency virus immunosuppression. Blood 81 3350-3356
163. Thorley-Lawson DA and Mann KP (1985) Early events in Epstein-Barr virus infection provide a model for B cell activation. Journal of Experimental Medicine 162 45-59
164. Tomkinson BE, Robertson E and Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA 3A and EBNA-3C are essential for B-lymphocyte growth transformation. Journal of Virology 67 2014-2025
165. Trevedi P, Hu LF, Christenssen B, Masucci MG, Klein G and Winberg G (1994) Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a
166. Van Gorp J, Weiping L, Jacobse K et al (1994) Epstein-Barr virus in nasal T cell lymphomas (polymorphic reticulosis/midline malignant reticulosis) in Western China. Journal of Pathology 173 81-87
167. Vousden KH (1994) Interactions between papillomavirus proteins and tumor suppressor gene products. Advances in Cancer Research 64 1-24
168. Waltzer L, Logeat F, Brou C, Israel A, Sergeant A and Manet E (1994) The human J K recombination signal sequence binding protein (RBP-J K) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO Journal 13 5663-5638
169. Wang D, Liebowitz D and Kieff E(1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Journal of Virology 43 831-840
170. Wei MX, Turenne-Tessier M, Decaussin G, Benet G and Ooka T (1997) Establishment of a monkey kidney epithelial cell line with the BARF-1 open reading frame of Epstein-Barr virus. Oncogene 14 3073-3081
171. Weiss LM, Movahead LA, Warnke RA and Sklar J (1989) Detection of Epstein-Barr virus genomes in Reed-Sternberg cells of Hodgkin's disease. New England Journal of Medicine 320 502-506
172. Wilson JB (1997) European EBV meeting, Munich, September 1997
173. Wilson JB, Weinberg W, Johnson R, Yuspa S and Levine AJ (1990) Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of Keratin 6. Cell 61 1315-1327
174. Wilson JB, Bell JL and Levine AJ (1996) Expression of Epstein-Barr virus nuclear antigen 1 induces B cell neoplasia in transgenic mice. EMBO Journal 15 3117-3126
175. Wu TC, Mann RB, Charache P et al (1990) Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. International Journal of Cancer 46 801-804
176. Yates JL, Warren N and Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 812-815
177. Ye BH, Lista F, Lo Coco F et al (1993) Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262 747-749
178. Young L, Alfieri C, Hennessy K et al (1989) Expression of Epstein-Barr virus transformation associated genes in tissues of patients with EBV lymphoproliferative disease. New England Journal of Medicine 321 1080-1085
179. Young LS, Rupani H, Busson P, Tursz T, Johnson A and Rickinson AB (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. Journal of General Virology 69 1051-1065
180. Zeidler R, Eissner G, Meissner P et al (1997) Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin 10. Blood 90 2390-2397
181. Zhang L and Pagano JS (1997) IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Molecular and Cellular Biology 17 5748-5757